Dr. Sonpavde on Enfortumab Vedotin Data in Urothelial Cancer

Guru P. Sonpavde, MD
Published: Wednesday, Oct 09, 2019



Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer. 
 
In the trial, patients who were previously treated with platinum-based chemotherapy and a PD-1/PD-L1 inhibitor and those who had not received platinum-containing chemotherapy or who are ineligible for cisplatin received enfortumab vedotin, an antibody-drug conjugate that targets Nectin-4, explains Sonpavde. 
 
Results from the trial showed a high objective response rate of 44%. Moreover, responses were reported irrespective of prior treatment with platinum-based chemotherapy or PD-1/PD-L1 inhibitors. Additionally, the median duration of response was 7.6 months. 
 
Encouragingly, investigators also reported complete responses in 12% of patients and robust responses in patients with liver metastases. Going forward, Sonpavde hopes enfortumab vedotin will be approved for clinical use in this patient population.  
SELECTED
LANGUAGE


Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer. 
 
In the trial, patients who were previously treated with platinum-based chemotherapy and a PD-1/PD-L1 inhibitor and those who had not received platinum-containing chemotherapy or who are ineligible for cisplatin received enfortumab vedotin, an antibody-drug conjugate that targets Nectin-4, explains Sonpavde. 
 
Results from the trial showed a high objective response rate of 44%. Moreover, responses were reported irrespective of prior treatment with platinum-based chemotherapy or PD-1/PD-L1 inhibitors. Additionally, the median duration of response was 7.6 months. 
 
Encouragingly, investigators also reported complete responses in 12% of patients and robust responses in patients with liver metastases. Going forward, Sonpavde hopes enfortumab vedotin will be approved for clinical use in this patient population.  



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x